We are international
• about imf TEXT SIZE   
imf funded research    back

Rationally Designed Pralatrexate Combination Therapies for MM
Hearn Jay Cho, MD
New York University Medical Center
New York,New York, USA

Pralatrexate is a new drug that is FDA-approved for lymphoma. The effectiveness of this drug is due in part to the presence of a molecule called RFC-1 on tumor cells, and RFC-1 levels in cancer cells can be increased by treatment wit certain drugs that affect gene expression.

Preliminary data indicate that pralatrexate can also kill myeloma cells that express RFC-1. We will determine if pralatrexate can be combined with drugs that increase RFC-1 to efficiently kill myeloma cells. Proof of this concept in laboratory studies may lead to clinical trials of these combinations in myeloma.

 related articles